French pharma representative body hits back at "blatant inadequacy" of social security financing law

The French industry body representing research-based pharma has spoken out against what it terms the “blatant inadequacy” of the draft French social security financing law and urges lawmakers to take into account the real challenges facing the healthcare system.

The French government is imposing strong regulation on the insurance budget spend on essential medicine, which Les entreprises du médicament (LEEM) says will make medicine the victim of a profoundly short-term plan.

The organization says there is disproportionate regulatory weight on medicines and that this is paralyzing the ability of the life science industry to perform at its best. Moreover, the suggested measures are unlikely to permanently put an end to the chronic deficit in health insurance.